Abstract Survival data stand out as a special statistical field. This paper tries to describe what survival data is and what makes it so special. Survival data concerns times to some events. A key point is the successive observation of time, which on the one hand leads to sometimes not being observed so that all that is known is that they exceed some given times (censoring), and on the other hand implies that predictions regarding the future course should be conditional on the present status (truncation). In the simplest case, this condition is that the individual is alive. The successive conditioning makes the hazard function, which describes the probability of an event happening during a short interval given that the individual is alive today, the most relevant concept. Here we discuss parametric as well as non-parametric methods. Examples are presented in a way that can be followed without the help of computers.
Introduction
First, we describe what survival data is in. What makes such data different from other types of data? In other words, why does the subject need a special statistical theory [1, 2] ? The answer is given in section on "Special Features of Survival Data" [3, 4] . We also try to answer some other questions:
What is hazard function and why is it so important [5] ? How are two survival functions compared [6] ? What is the role of nonparametric methods?
Survival Data
Survival data is a term used for data measuring the time to some event. In the simplest case, the event is death, but the term also covers other events, like disease recurrence (e.g. cancer), occurrence of a disease, a complication, or, e.g., the time to occurrence of an epileptic seizure. The study participants are "at risk" for the event continuously over time from the start of the observation. The duration of observation may vary from one subject to another, e.g., staggered entry into a clinical trial. The observation may be shortened by lost contact or other non-relevant competing risks.
Survival data consider only a single or a few types of states and events, ruling out the possibility of continuous measurements of, e.g., quality of life. To study such a concept, it must be classified into a few well-defined groups. On the other hand, the time to event is considered in great detail in survival analysis. The biostatistical tradition for times for human beings is to count days and then analyze them by rank-based (nonparametric) methods. For example, for studies of cancer, this does not make medical sense because cancers can be developing for up to 3-4 years before being diagnosed [7] . Grouping cancers into years might be acceptable from a medical point of view but is unacceptable as the nonparametric methods might have too many coinciding observations (ties) [1, 2] . take longer times to observe than smaller ones. Time is observed sequentially. A consequence of this is: presence of censored data SPSS16.0 [8, 9] .
Censored Data
Censoring of data can occur due to loss to follow up, or because the subject withdraws from the study (e.g. because of an adverse drug reaction), or because the subject does not experience the event before the study ends. There are three kinds of censoring-right, left and random (Fig. 1) . The first patient developed the event at 5 years. But in the second patient, the event did not occur until the end of study. The third patient entered the study during the second year and withdrew at 6 years. This patient's contribution to the study was 4 years of follow up. The second and third patients' survival time was incomplete at the end of study and were right censored. Left censored data can occur when a subject's survival time is incomplete at the beginning of follow up period. For example, if we were following subjects with HIV infection, we might start the follow up when a subject's first test was positive for the HIV virus, but we may not know the exact time of the first viral infection.
Analysis of Survival Data

Survivor Function
The most obvious and natural way of summarizing survival data is a survivor function (or survival curve) [10] which is the proportion of subjects remaining event-free at each point in time from the start of the observation. This would be extremely simple if all subjects were followed up to some common time, say 5 years. The problem arises when a subject's observation stops at say, 18 months, i.e. it is censored. Censored observations contribute to the estimation of the survival curve up to the time of censoring. The survivor curve is calculated by the successive multiplication of the probability of having an event in each earlier time period.
Kaplan-Meier Estimate
Assume we have events occurring at times t 1 , t 2 ,......, t k which are ordered in increasing time. Then from the Multiplication Law of Probability:
Prob alive beyond t j À Á ¼ Prob alive just before t j À Á Â Prob not dying at t j À Á or in a shorter notation:
The survival curve is then constructed as a step function with downward steps at each event times t j . Thus S(t j + ) equals S(t j+1 -) and so the curve becomes a series of multiplications.
At each event time t j
Number of subjects not having an event at t j Number of subjects at risk at t j
where n j subjects are at risk at time t j and d j subjects have an event, at t j . This procedure is called the Kaplan-Meier product moment estimator [11] of the survivor function and assumes that the individual time of each event or each end of observation is known for all subjects. The calculations are organized in columns, The standard error in the far right hand column is computed from Greenwood's formula as:
and can be used to place an approximate 95 % confidence interval on S(t j ) in the usual way as,
The estimated survival curve is plotted in Fig. 2 .
Hazard Function
While the survivor function focuses on the probability of not failing, the hazard function [12, 13] focuses on failing. In many situations, it is important to know how the hazard (risk) of a particular outcome changes with time. For example, it is well known that infant mortality is highest in the few days following birth and thereafter declines very rapidly. The hazard function, h(t), gives the instantaneous risk per unit time for the event (death, relapse, etc.) to occur, given that the individual has survived up to time t. This is defined as;
hðtÞ
In other words given that a subject has not had an event up to time t the hazard is the probability that the subject will have an event in the next small time interval. We often want to look at the way hazard changes over time. To do this we must divide time up to intervals and calculate an average hazard for each interval as, hðtÞ ¼ Number of events in interval Sum of time at risk for subjects in interval Using an interval of 30 days with the earlier data results in Table 1 . All the patients were resected before treatment began and thus have no evidence of melanoma at the time of first treatment.
The usual objective of this type of data is to determine the length of remission and survival and to compare the distributions of remission and survival time in each group. Before comparing the remission and survival distributions, we must examine if the two treatment groups are comparable with respect to prognostic factors. Let us use survival time to illustrate the steps. (The remission time could be similarly analyzed).
For such samples with progressively censored observations, the Kaplan-Meier product-limit (PL) method is appropriate for estimating the survival function. It does not require any assumptions about the form of the function that is being estimated. We have used SPSS 16.0 to find survival curves. Table 3 gives the PL estimate of the survival function for the two treatment groups.
The median survival time for BCG patients was 19.5 months. The median survival time for the C.parvum group can not be calculated since 14 of the 19 patients were still alive. Figure 3 plots the estimated survival function S(t) for patients receiving the two treatments. The median survival time for BCG group can also be determined graphically. The survival curves clearly show that C. parvum patients had slightly better survival experience than BCG patients. For example, 50 % of the BCG patients survived at least 19.5 months while about 61 % of the C. parvum patients survived that long. Using Logrank test, the difference in survival distribution of the two treatment groups is found to be insignificant (p0 0.387). Therefore the data do not provide enough evidence to reject the hypothesis that the two survival distributions are same.
Comparison of Tests
When sample sizes are small (<50), Cox's F-test is more powerful than Gehan's generalized Wilcoxon's test if samples are from exponential or Weibull distributions and if there are no censored observations or the observations are singly censored. When samples are from exponential distributions, with or without censoring the Cox-Mantel and logrank tests are more powerful and more efficient than the generalized Wilcoxon tests of Gehan and Peto and Peto. There is little difference between the Cox-Mantel and the logrank tests and the two generalzed Wilcoxon tests. When the samples are taken from Weibull distributions with constant hazard ratio (i.e., the ratio of the two hazard functions does not vary with time), the results are essentially the same as in the exponential case. However, when the hazard ratio is nonconstant, the two generalizations of the Wilcoxon test have more power than the other tests. Thus, the logrank test is more powerful than the Wilcoxon tests in detecting departures when the two hazard functions are parallel (proportional hazard) or there is random but equal censoring and when there is no censoring in the samples.
The generalized Wilcoxon tests give more weight to early failures than later failures whereas the logrank test gives equal weight to all failures. Therefore, the generalized Wilcoxon tests are more likely to detect early differences in the two survival distributions whereas the logrank test is more sensitive to differences at the right tails. If heavy censoring exists, Gehan's statistic is dominated by a small number of early failures and has low power.
There are situations in which neither the logrank nor the Wilcoxon tests are very effective. When the two distributions differ but their hazard functions or survivorship functions cross, neither the Wilcoxon nor the logrank test is very powerful and it will be sensible to consider other tests. For example, Tarone and Ware [14] discuss general statistics of similar form (using scores) and Fleming et al. [15] present a two-sample test based on a Smirnov-type statistic designed to measure the maximum distance between estimates of two distributions. The latter approach is shown to be more effective than the logrank or Wilcoxon tests when the two survival distributions differ substantially for some range of t values but not necessarily elsewhere.
SPSS 16.0 version can be used to find Kaplan-Meier estimates and the tests such as : (i) logrank test, (ii) Tarone-Ware test and (iii) Breslow test.
Discussion
Here we have presented the survival analysis of the data in a way that it can be followed simply and without the help of the computers as well as using computer softwares. The detailed calculations will give an insight into the understanding of the subject matter. Of course, the softwares, such as SPSS and STATA are available for the purpose, but their rationale and appropriate use cannot be accomplished without the proper knowledge of the subject.
